Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 0.64 |
| ▸ | ERBB4 known ✓ | Q15303 | 9/20 | 0.64 |
| ▸ | ERBB2 known ✓ | P04626 | 15/20 | 0.63 |
| ▸ | JAK3 known ✓ | P52333 | 2/20 | 0.60 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.60 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.60 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | MC3R | P41968 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19100423 | 0.97 | EGFR (0.67) | EGFRERBB4ERBB2JAK3GAK | |
| SCHEMBL19100190 | 0.92 | EGFR (0.67) | EGFRERBB4ERBB2JAK3GAK | |
| SCHEMBL19100063 | 0.91 | EGFR (0.67) | EGFRERBB4ERBB2JAK3GAK | |
| SCHEMBL19123928 | 0.89 | EGFR (0.63) | EGFRERBB4ERBB2JAK3GAK | |
| SCHEMBL19100269 | 0.89 | EGFR (0.64) | EGFRERBB4ERBB2JAK3GAK | |
| SCHEMBL19100094 | 0.88 | EGFR (0.66) | EGFRERBB4ERBB2JAK3GAK | |
| SCHEMBL19123783 | 0.87 | EGFR (0.58) | EGFRERBB4ERBB2JAK3GAK | |
| Maleic Acid SCHEMBL20637507 | 0.87 | EGFR (0.67) | EGFRERBB4ERBB2GAKRIPK2 | |
| SCHEMBL19100301 | 0.87 | EGFR (0.85) | EGFRERBB4ERBB2JAK3GAK | |
| SCHEMBL19125881 | 0.86 | EGFR (0.58) | EGFRERBB2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB4 3/4885ERBB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.